Remus Pharmaceuticals results
NSE: REMUSPharmaceuticals & Biotechnology
Last close ₹880.60down ₹20.60 (2.29%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹901.20.
52-week range of traded prices to 23 Oct 2026
₹580.00Low, 9 Mar 2026₹1,039.00High, 15 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹1,038 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 20 May 2026
- 28.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 20 May 2026
- 3.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 20 May 2026
- 12.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 20 May 2026
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 20 May 2026
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,80085.7% delivered
Results for the half year to Mar 2026
Consolidated: the company and its subsidiaries together. ₹ crore.Remus Pharmaceuticals annual results and balance sheet
- RevenueRevenue from operations. Money earned from selling the company's goods and services in the period.
- ₹453 Cr+30.4% on a year ago · +13.3% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Operating profitOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax.
- ₹30 Cr+21.5% on a year ago · +10.7% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Net profitNet profit. What is left of revenue and other income after every cost, interest and tax.
- ₹25 Cr+19.5% on a year ago · +13.8% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line.
- ₹20.86+19.5% on a year ago · +13.8% on the half year beforeChange on a year ago. The change against the same half year a year before: (this half year's figure less that half year's) divided by that half year's, times 100. Left out where either figure is a loss, or across a change of basis named under the table, on the lines it affects.
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs.
- 6.6%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.4%
From revenue to net profit, ₹ crore
- Revenue453
- Materials and goods−393
- Employee costs−6.6
- Other expenses−24
- Operating profit30
- Depreciation−1.5
- Other income+3.8
- Finance costs−0.8
- Profit before tax31
- Tax−6.7
- Net profit25
Remus Pharmaceuticals results by half year
Consolidated: the company and its subsidiaries together. Latest half year to Mar 2026. Results for the half year to Sep 2026 are due by 14 Nov 2026, 45 days after it ends.Results filings and date
Revenue and net profit by half year, ₹ crore
- Revenue
- Net profit
Operating and net margin by half year, per cent
- Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs.
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
| ₹ crore | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025Filed 19 May | Sep 2025Filed 10 Nov | Mar 2026Filed 20 May |
|---|---|---|---|---|---|---|
| Revenue from operations | 29 | 183 | 273 | 348 | 400 | 453 |
| Operating expenses. What the business spent to run itself in the period, materials, staff and other costs, before depreciation, interest and tax. | 20 | 165 | 252 | 323 | 373 | 424 |
| Materials and goods boughtCost of materials and goods. Raw materials used and goods bought for resale in the period, adjusted for the change in stock held. | 14 | 151 | 232 | 301 | 350 | 393 |
| Employee costsEmployee costs. Salaries, wages, bonuses and other benefits paid to staff in the period. | 3 | 4 | 6 | 7 | 6 | 7 |
| Other expensesOther expenses. Every operating cost besides materials and staff: power, rent, freight, repairs, marketing and the like. | 3 | 10 | 14 | 15 | 18 | 24 |
| Operating profit before depreciationOperating profit before depreciation (EBITDA). Revenue less operating expenses: what the business earns from its operations before depreciation, interest and tax. | 9 | 19 | 21 | 25 | 27 | 30 |
| Operating marginOperating margin. Operating profit before depreciation as a percentage of revenue: how much of each rupee of sales is left after running costs. | 31.9% | 10.1% | 7.5% | 7.1% | 6.7% | 6.6% |
| Depreciation and amortisationDepreciation and amortisation. The part of the cost of plant, buildings and other long-lived assets charged against each year they are used. | 0 | 0 | 0 | 1 | 1 | 1 |
| Other incomeOther income. Income from outside the main business, such as interest on deposits, dividends received and gains on investments. | 2 | 4 | 3 | 3 | 3 | 4 |
| Finance costsFinance costs. Interest and the other costs of borrowing in the period. | 0 | 0 | 1 | 1 | 1 | 1 |
| One-off itemsExceptional items. Gains or losses the company reports separately because they are not expected to recur, such as selling a business or writing down an asset. | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 10 | 21 | 22 | 25 | 28 | 31 |
| 3 | – | 3 | 5 | 6 | 7 | |
| Tax rateEffective tax rate. Tax charged as a percentage of profit before tax. | 25.0% | – | 15.6% | 18.9% | 22.6% | 21.4% |
| Share of profit of joint ventures and associatesShare of profit of joint ventures and associates. The group's share of the profit of companies it part-owns and does not consolidate, as stated. It is part of net profit but not of revenue or operating profit: their sales and costs are not in the group's lines. | −2 | – | – | – | – | – |
| 6 | 16 | 14 | 21 | 22 | 25 | |
| Other comprehensive incomeOther comprehensive income. Gains and losses booked straight to net worth rather than through profit, such as changes in the value of some investments, pension plans and currency translation. | – | – | – | 70 | 34 | 26 |
| Total comprehensive incomeTotal comprehensive income. Net profit plus other comprehensive income. | – | – | – | 91 | 55 | 51 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 19.4% | 8.7% | 5.1% | 5.9% | 5.4% | 5.4% |
| Net margin without joint ventures and associatesNet margin without joint ventures and associates. Net profit less the share of profit of joint ventures and associates, as a percentage of revenue: the margin on the businesses whose revenue the statement carries. Shown where the company states such a share. | 26.9% | – | – | – | – | – |
| Earnings per shareEarnings per share. Profit belonging to shareholders divided by the number of shares, restated for later splits and bonuses so they do not break the line. | – | – | – | ₹17.46 | ₹18.33 | ₹20.86 |
Earnings per share in rupees, restated for later splits and bonuses.
Filed results, as an XML file each
- Results for the half year to Mar 2026 (opens in a new tab)Filed 20 May 2026, audited
- Results for the half year to Sep 2025 (opens in a new tab)Filed 10 Nov 2025, unaudited
- Results for the half year to Mar 2025 (opens in a new tab)Filed 19 May 2025, audited